Gastroenterology and Digestive Oncology Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.
Gastroenterology and Digestive Oncology Unit, Georges Pompidou Hospital, APHP, Paris, France; UMR-S775, INSERM, Paris, France.
Dig Liver Dis. 2014 Feb;46(2):97-104. doi: 10.1016/j.dld.2013.04.013. Epub 2013 Jun 21.
Small bowel adenocarcinomas are rare tumours, but their incidence is increasing. Their most common primary location is the duodenum. The few studies that have collected data regarding small bowel adenocarcinoma are not homogeneous and are widely spread over time. Even though these tumours are most often sporadic, some predisposing diseases have been identified, among which Crohn's disease and genetic syndromes. Early diagnosis of small bowel adenocarcinoma remains difficult despite significant radiological and endoscopic progress. After surgical resection the main prognostic factor is node invasion; in this case, adjuvant chemotherapy can be expected to be beneficial, although this has not been established by randomised trials. For metastatic disease, platinum-based chemotherapy seems to be the most effective treatment. Targeted therapies have not yet been evaluated in this type of cancer.
小肠腺癌是一种罕见的肿瘤，但发病率正在上升。它们最常见的原发部位是十二指肠。少数收集小肠腺癌数据的研究并不具有同质性，而且时间跨度很大。尽管这些肿瘤通常是散发性的，但已经确定了一些易患疾病，其中包括克罗恩病和遗传综合征。尽管在影像学和内镜方面取得了显著进展，但小肠腺癌的早期诊断仍然很困难。手术切除后，主要的预后因素是淋巴结侵犯；在这种情况下，辅助化疗可能有益，尽管这尚未通过随机试验确定。对于转移性疾病，基于铂类的化疗似乎是最有效的治疗方法。在这种类型的癌症中，尚未评估靶向治疗。
